Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect

Felix Stader 1,2*, Saye Khoo3, Marcel Stoeckle1,2, David Back3, Hans H. Hirsch1,4, Manuel Battegay1,2 and Catia Marzolini1–3

1Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital Basel, Basel, Switzerland; 2University of Basel, Basel, Switzerland; 3Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK; 4Transplantation & Clinical Virology, Department of Biomedicine, University of Basel, Basel, Switzerland

*Corresponding author. E-mail: Felix.Stader@usb.ch

Sir, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is highly infectious, causing coronavirus infectious disease 2019 (COVID-19) worldwide.1 One of the experimental treatments includes the HIV drug lopinavir boosted with ritonavir. Both PIs cause irreversible mechanism-based inhibition (loss of metabolizing enzymes) and induction of metabolizing enzymes in the liver and intestine, which often leads to drug–drug interactions (DDIs) with co-medications.2 The duration of cytochrome P-450 (CYP) 3A inhibition after stopping lopinavir/ritonavir treatment is not well understood, leading to some uncertainty as to how long to maintain adjusted doses of co-medications or when to restart drug therapies against comorbidities.

We investigated the duration of hepatic and intestinal CYP3A inhibition after stopping lopinavir/ritonavir treatment by a verified modelling approach.3 Lopinavir/ritonavir (400/100 mg twice daily) was administered for 7 days in a virtual trial to achieve steady-state CYP3A inhibition and the abundance of CYP3A was estimated for 21 consecutive days. The interaction potential after stopping lopinavir/ritonavir was investigated with the CYP3A probe substrate midazolam. Midazolam was administered orally (5 mg once daily) starting on the seventh day of the study. Simulations were performed in the four age categories 20 to 50 years, 60 to 69 years, 70 to 79 years and 80 to 89 years, because severe COVID-19 outcome is more likely in older individuals having comorbidities.4 Our model takes age-related physiological changes into account.3 These include a decrease in hepatic and renal blood flow and glomerular filtration rate, which lead to a decline in drug clearance. Furthermore, body composition changes with advanced age, towards more adipose tissue weight and lower body water, which does, however, not affect the volume of distribution.5,6 In each age group, 100 subjects (50% women) in 10 trials were simulated. The reduction in DDI magnitude for midazolam was calculated using the last day of lopinavir/ritonavir administration as a basis. Results are reported as mean (95% CI).

CYP3A inhibition decreased profoundly 24 h after stopping lopinavir/ritonavir, with a 61% (17%–80%) and 46% (8%–80%) reduction in adults aged 20 to 50 years and 80 to 89 years, respectively [Table 1 and Figure S1 (available as Supplementary data at JAC Online)]. The temporal decrease in CYP3A inhibition was slower 3 days after stopping lopinavir/ritonavir compared with the first day post-COVID-19 treatment, meaning that the initial novel CYP3A synthesis is fast in the first hours after discontinuing the strong mechanism-based CYP3A inhibitor and becomes saturated after 72 h. In all age groups, there was more than 80% disappearance of CYP3A inhibition 5 days after stopping lopinavir/ritonavir under the consideration of population variability. Complete disappearance of CYP3A inhibition took 21 days in all simulated age groups.

The experimental COVID-19 treatment lopinavir/ritonavir irreversibly inhibits CYP3A. After stopping the treatment, CYP3A needs to be synthesized, which depends on the turnover rate of CYP3A rather than the half-life of lopinavir/ritonavir, leading to a longer inhibition as opposed to competitive inhibition.7 We demonstrated that the CYP3A inhibitory effect was reduced by 80% after 48 h in adults aged 20 to 50 years and after 72 h in adults at least 60 years old, who are more likely to have severe COVID-19 outcomes and be taking more co-medications.4 Thus, pre-COVID-19 treatments can be restarted at normal doses 2 to 3 days after stopping lopinavir/ritonavir for most individuals. However, given the physiological variability of COVID-19 patients, which leads to variability in the DDI magnitudes (see the 95% CI in Table 1), we suggest standard doses of co-medication can be safely given on the fifth day after stopping lopinavir/ritonavir to all hospitalized COVID-19 patients.

Lopinavir/ritonavir does not only inhibit CYP3A, but also induces CYP2C9, CYP2C19 and CYP1A2.2 Induction implies new synthesis of enzymes and therefore resolution can take up to 3 weeks.8 Narrow therapeutic-index drugs induced by lopinavir/ritonavir, which warrant monitoring, include for instance vitamin K antagonists.

It is also important to note that COVID-19 leads to a cytokine storm with elevated IL-6 concentrations,9 which may also irreversibly inhibit CYP3A, although to a lesser extent than lopinavir/ritonavir.10 Thus, careful monitoring of co-medications metabolized by CYP3A is important since doses may need to be adjusted in all hospitalized COVID-19 patients with the return to pre-COVID-19 doses in the same time range as reported here for lopinavir/ritonavir.

Funding
F.S. was supported by a grant from the Swiss National Foundation (grant number: 324730_188504). C.M. was supported by the Adolf and Mary-Mil Foundation. All other authors did the study as part of their routine work.

© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.

J Antimicrob Chemother
doi:10.1093/jac/dkaa253

Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect
Table 1. Disappearance of hepatic and intestinal CYP3A inhibition after stopping lopinavir/ritonavir treatment

| Day after stopping lopinavir/ritonavir | Disappearance of hepatic and intestinal CYP3A inhibition (%) |
|---------------------------------------|----------------------------------------------------------|
|                                       | 20–50 years | 60–69 years | 70–79 years | 80–89 years |
|                                       | mean | 95% CI | mean | 95% CI | mean | 95% CI | mean | 95% CI |
| 0                                     | 0 | 0–0 | 0 | 0–0 | 0 | 0–0 | 0 | 0–0 |
| 1                                     | 61 | 17–80 | 51 | 9–78 | 50 | 8–76 | 46 | 8–80 |
| 2                                     | 80 | 61–91 | 76 | 47–91 | 74 | 18–89 | 71 | 10–92 |
| 3                                     | 87 | 77–95 | 87 | 72–95 | 84 | 53–94 | 81 | 12–96 |
| 4                                     | 91 | 84–97 | 91 | 82–97 | 89 | 74–96 | 88 | 67–97 |
| 5                                     | 94 | 88–98 | 93 | 87–98 | 92 | 82–97 | 92 | 83–98 |
| 6                                     | 95 | 91–98 | 95 | 90–98 | 94 | 87–98 | 94 | 89–99 |
| 7                                     | 96 | 93–99 | 96 | 92–99 | 96 | 90–98 | 95 | 92–99 |
| 14                                    | 99 | 98–100 | 99 | 98–100 | 99 | 98–100 | 99 | 98–100 |
| 21                                    | 100 | 100–100 | 100 | 100–100 | 100 | 100–100 | 100 | 100–100 |

References

1. Cao B, Wang Y, Wen D et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382: 1787–99.
2. Yeh RF, Gaver VE, Patterson KB et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006; 42: 52–60.
3. Stader F, Penny MA, Siccardi M et al. A comprehensive framework for physiologically based pharmacokinetic modelling in Matlab®. CPT Pharmacometrics Syst Pharmacol 2019; 8: 444–59.
4. Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054–62.
5. Stader F, Siccardi M, Battegay M et al. Repository describing an aging population to inform physiologically based pharmacokinetic models considering anatomical, physiological, and biological age-dependent changes. Clin Pharmacokinet 2019; 58: 483–501.
6. Stader F, Kinvig H, Penny MA et al. Physiologically based pharmacokinetic modelling to identify pharmacokinetic parameters driving drug exposure changes in the elderly. Clin Pharmacokinet 2020; 59: 383–401.
7. Rowland-Yeo K, Walsky R, Jamei M et al. Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover. Eur J Pharm Sci 2011; 43: 160–73.
8. Magnusson M, Dahl M, Cederberg J et al. Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. Clin Pharmacol Ther 2008; 84: 52–62.
9. Yuan J, Zou R, Zeng L et al. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. Inflamm Res 2020; 69: 599–606.
10. Dickmann LJ, Patel SK, Rock DA et al. Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metab Dispos 2011; 39: 1415–22.